9. Other operating expenses/income

| | | 2023 | | | 2022 | |
|---|---------|-----------------|----------|---------|-----------------|----------|
| | | Exceptional | | | Exceptional | |
| | 2023 | items and other | 2023 | 2022 | items and other | 2022 |
| | Core | adjustments | Reported | Core | adjustments | Reported |
| | results | (Note 6) | results | results | (Note 6) | results |
| Other operating expenses | \$m | \$m | \$m | \$m | \$m | \$m |
| Impairment charges (Notes 15, 16 and 17) | - | 70 | 70 | 1 | 181 | 182 |
| Forex and net monetary hyperinflation losses, net | 5 | 1 | 6 | 20 | _ | 20 |
| Others | 4 | - | 4 | 4 | _ | 4 |
| | 9 | 71 | 80 | 25 | 181 | 206 |

Impairment charges (excluding Sudan) comprise \$32 million related to product related intangible assets, marketing rights intangible assets and software, \$30 million related to Sudan exposure, and \$8 related to right-of-use assets and property, plant and equipment (Notes 6, 15, 16 and 17). In 2022, impairment charges of \$182 million primarily related to excess capacity due to the rationalisation of the Generics R&D pipeline and associated production lines in addition to the impairment of generic Advair Diskus CGU (Notes 6, 15, 16 and 17).

| | | 2023 | | | 2022 | |
|---|---------|-----------------|----------|---------|-----------------|----------|
| | | Exceptional | | | Exceptional | |
| | 2023 | items and other | 2023 | 2022 | items and other | 2022 |
| | Core | adjustments | Reported | Core | adjustments | Reported |
| | results | (Note 6) | results | results | (Note 6) | results |
| Other operating income | \$m | \$m | \$m | \$m | \$m | \$m_ |
| Gain from disposal of property, plant and equipment | - | - | - | 1 | _ | 1 |
| Gain from disposal of intangible assets | - | _ | - | 6 | _ | 6 |
| Others | 5 | - | 5 | 7 | _ | 7 |
| | 5 | - | 5 | 14 | _ | 14 |

10. Finance income

| | | 2023 | | | 2022 | |
|---|---------|-----------------|----------|---------|-----------------|----------|
| | | Exceptional | | | Exceptional | |
| | 2023 | items and other | 2023 | 2022 | items and other | 2022 |
| | Core | adjustments | Reported | Core | adjustments | Reported |
| | results | (Note 6) | results | results | (Note 6) | results |
| | \$m | \$m | \$m | \$m | \$m | \$m |
| Interest income | 7 | _ | 7 | 3 | _ | 3 |
| Remeasurement of contingent consideration | | | | | | |
| (Notes 6, 27, 29 and 30) | _ | - | - | - | 26 | 26 |
| | 7 | _ | 7 | 3 | 26 | 29 |

11. Finance expense

| | | 2023 | | | 2022 | |
|---|-----------|-----------------------------|-----------|-----------|-----------------------------|-----------|
| | 2023 | Exceptional items and other | 2023 | 2022 | Exceptional items and other | 2022 |
| | Core | | Reported | Core | adjustments | Reported |
| | results | • • • • • • • | results | results | (Note 6) | results |
| Interest on bank overdrafts and loans | \$m 51 | \$m _ | \$m 51 | \$m 37 | \$m _ | \$m 37 |
| Interest on Eurobond | 18 | _ | 18 | 18 | _ | 18 |
| Unwinding and remeasurement of contingent consideration and other financial liabilities | | | | | | |
| (Notes 6, 27, 29 and 30) | - | 5 | 5 | _ | 4 | 4 |
| Other bank charges | 14 | - | 14 | 11 | _ | 11 |
| Lease accretion of interest (Note 17) | 4 | - | 4 | 4 | _ | 4 |
| Net foreign exchange loss | 3 | - | 3 | 7 | _ | 7 |
| | 90 | 5 | 95 | 77 | 4 | 81 |